Amendment #17 to H4891

ADA diabetes equipment and supplies

Ms. Giannino of Revere moves to amend the amendment by adding the following section

(Chapter 32A)

In Section 27, add to the end thereof:

(h) If use of a brand name drug or generic drug that the commission selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The commission shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(i) The commission shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The commission shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(k) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

(Chapter 118E)

In Section 29, add to the end thereof:

(i) If use of a brand name drug or generic drug that the division selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The division shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The division shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(k) The division shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(l) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

(Chapter 175)

In Section 30, add to the end thereof:

(h) If use of a brand name drug or generic drug that the carrier selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The carrier shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(i) The carrier shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The carrier shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(k) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

(Chapter 176A)

In Section 32, add to the end thereof:

(h) If use of a brand name drug or generic drug that the carrier selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The carrier shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(i) The carrier shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The carrier shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(k) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

(Chapter 176B)

In Section 33, add to the end thereof:

(h) If use of a brand name drug or generic drug that the carrier selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The carrier shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(i) The carrier shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The carrier shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(k) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

(Chapter 176G)

In Section 34, add to the end thereof:

(h) If use of a brand name drug or generic drug that the carrier selects requires a separate delivery device, the commission shall select a delivery device for that drug in accordance with the criteria established in subsection (c) for selecting brand name drugs and generic drugs, to the extent possible. The carrier shall provide coverage for the delivery device and the delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(i) The carrier shall provide coverage for the continuous glucose monitoring system component selected pursuant to subsection (b) and all components of the blood glucose monitoring system of which the selected component is a part. All components of the applicable continuous glucose monitoring system shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible

(j) The carrier shall provide coverage for the necessary diabetes treatment supplies. Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any deductible.

(k) If a high deductible health plan subject to this section is used to establish a savings account that is tax-exempt under the federal Internal Revenue Code, the provisions of this section shall apply to the plan to the maximum extent possible without causing the account to lose its tax-exempt status.

Additional co-sponsor(s) added to Amendment #17 to H4891

ADA diabetes equipment and supplies